

Yasuhiro Nagai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7885659/publications.pdf>

Version: 2024-02-01

10
papers

461
citations

933447

10
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

705
citing authors

#	ARTICLE	IF	CITATIONS
1	Foxp3 Post-translational Modifications and Treg Suppressive Activity. <i>Frontiers in Immunology</i> , 2019, 10, 2486.	4.8	90
2	Dynamic Interactions between TIP60 and p300 Regulate FOXP3 Function through a Structural Switch Defined by a Single Lysine on TIP60. <i>Cell Reports</i> , 2014, 7, 1471-1480.	6.4	89
3	Pim-2 Kinase Influences Regulatory T Cell Function and Stability by Mediating Foxp3 Protein N-terminal Phosphorylation. <i>Journal of Biological Chemistry</i> , 2015, 290, 20211-20220.	3.4	74
4	PRMT5 Associates With the FOXP3 Homomer and When Disabled Enhances Targeted p185erbB2/neu Tumor Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 174.	4.8	56
5	Suppression by human FOXP3 ⁺ regulatory T cells requires FOXP3-TIP60 interactions. <i>Science Immunology</i> , 2017, 2, .	11.9	47
6	PRMT5 Is Required for T Cell Survival and Proliferation by Maintaining Cytokine Signaling. <i>Frontiers in Immunology</i> , 2020, 11, 621.	4.8	36
7	Disabling of the erbB Pathway Followed by IFN- $\hat{3}$ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors. <i>Cell Reports</i> , 2015, 12, 2049-2059.	6.4	25
8	FOXP3 and Its Cofactors as Targets of Immunotherapies. <i>Engineering</i> , 2019, 5, 115-121.	6.7	21
9	A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon- $\hat{3}$. <i>Oncolmmunology</i> , 2018, 7, e1300739.	4.6	12
10	A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77. <i>Oncotarget</i> , 2018, 9, 3631-3640.	1.8	11